Several analysts have recently updated their ratings and price targets for Traws Pharma (NASDAQ: TRAW):

• 6/18/2026 – Traws Pharma had its “negative” rating reaffirmed by HC Wainwright. They now have a $1.00 price target on the stock.
• 6/18/2026 – Traws Pharma was downgraded by HC Wainwright from “buy” to “hold”. They now have a $1.00 price target on the stock.
• 6/15/2026 – Traws Pharma was downgraded by Citigroup Inc. to “neutral”.
• 6/15/2026 – Traws Pharma was downgraded by LADENBURG THALM/SH SH from “buy” to “neutral”.
• 6/13/2026 – Traws Pharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/30/2026 – Traws Pharma was downgraded by Wall Street Zen to “strong sell”.
• 5/29/2026 – Traws Pharma was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.
• 5/20/2026 – Traws Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 5/15/2026 – Traws Pharma was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.

Insider Buying and Selling

In related news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the purchase, the insider directly owned 1,203,250 shares in the company, valued at $2,009,427.50. The trade was a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 7.57% of the company’s stock.

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.

Recommended Stories

• Five stocks we like better than Traws Pharma
• Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
• This Under-the-Radar Industrial Is Quietly Powering AI
• Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
• Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares

Receive News & Ratings for Traws Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.